Caricamento...
Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious
BACKGROUND: A median progression free survival (PFS) of 18–20 months and median overall survival (OS) of 51–57 months can be achieved with the use of imatinib, in metastatic or advanced gastrointestinal stromal tumor (GIST). Sunitinib and regorafenib are approved options for patients progressing on...
Salvato in:
| Pubblicato in: | J Gastrointest Oncol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
AME Publishing Company
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4963378/ https://ncbi.nlm.nih.gov/pubmed/27563456 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.06 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|
Caricamento...